Thoroughbred Financial Services, LLC Novo Nordisk A S Transaction History

Thoroughbred Financial Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$58.08 - $81.05 $816,662 - $1.14 Million	-14,061 Reduced 72.52%	5,327 $367,000
Q1 2025 May 09, 2025	SELL	$69.3 - $90.95 $1.65 Million - $2.17 Million	-23,857 Reduced 55.17%	19,388 $1.35 Million
Q4 2024 Feb 12, 2025	BUY	$85.0 - $120.04 $122,740 - $173,337	1,444 Added 3.45%	43,245 $3.72 Million
Q3 2024 Nov 08, 2024	SELL	$119.07 - $145.42 $193,369 - $236,162	-1,624 Reduced 3.74%	41,801 $4.98 Million
Q2 2024 Aug 08, 2024	BUY	$122.71 - $146.91 $2.69 Million - $3.22 Million	21,903 Added 101.77%	43,425 $6.2 Million

Q1 2024 May 07, 2024	SELL	$102.11 - $135.92 $1.35 Million - $1.79 Million	-13,182 Reduced 37.98%	21,522 $2.76 Million
Q4 2023 Feb 09, 2024	BUY	$87.78 - $105.45 $1.33 Million - $1.6 Million	15,167 Added 77.63%	34,704 $3.59 Million
Q3 2023 Nov 08, 2023	BUY	$90.94 - $199.54 $1.66 Million - $3.64 Million	18,253 Added 1421.57%	19,537 $1.78 Million
Q2 2023 Aug 03, 2023	BUY	$155.98 - $172.65 $200,278 - $221,682	1,284 New	1,284 $207,000

1,689

303M

25.9M

43.8M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $109B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Thoroughbred Financial Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Thoroughbred Financial Services, LLC with notifications on news.